184 related articles for article (PubMed ID: 34403037)
1. Generation and Characterization of a Nanobody Against SARS-CoV.
Li JF; He L; Deng YQ; Qi SH; Chen YH; Zhang XL; Hu SX; Fan RW; Zhao GY; Qin CF
Virol Sin; 2021 Dec; 36(6):1484-1491. PubMed ID: 34403037
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
3. Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein.
Su Q; Shi W; Huang X; Wan Y; Li G; Xing B; Xu ZP; Liu H; Hammock BD; Yang X; Yin S; Lu X
Cells; 2022 Oct; 11(21):. PubMed ID: 36359751
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
Viruses; 2023 May; 15(6):. PubMed ID: 37376552
[TBL] [Abstract][Full Text] [Related]
6. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
Front Immunol; 2022; 13():820336. PubMed ID: 35663966
[TBL] [Abstract][Full Text] [Related]
7. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
8. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
9. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
[TBL] [Abstract][Full Text] [Related]
10. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
[TBL] [Abstract][Full Text] [Related]
11. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
12. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
13. A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site.
He S; Wang J; Chen H; Qian Z; Hu K; Shi B; Wang J
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851249
[TBL] [Abstract][Full Text] [Related]
14. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M
Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271
[TBL] [Abstract][Full Text] [Related]
15. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
16. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
[TBL] [Abstract][Full Text] [Related]
17. A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein.
Zhang Y; Wang D; Xiang Q; Hu X; Zhang Y; Wu L; Zhang Z; Wang Y; Zhao J; McCormick PJ; Fu J; Fu Y; Zhang J; Jiang H; Li J
Virology; 2024 Jan; 589():109925. PubMed ID: 37984151
[TBL] [Abstract][Full Text] [Related]
18. A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.
Wu P; Yang Q; Zhao X; Liu Q; Xi J; Zhang F; He J; Yang H; Zhang C; Ma Z; Deng X; Wang Y; Chen C
Res Vet Sci; 2022 Jul; 145():46-49. PubMed ID: 35152188
[TBL] [Abstract][Full Text] [Related]
19. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry.
Abduljaleel Z; Shahzad N; Aziz SA; Malik SM
Mol Divers; 2023 Apr; 27(2):695-708. PubMed ID: 35616802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
